Expertise in
7
conditions

Boris Duchemann

Bobigny, FR 
Expertise in
7
conditions
Bobigny, FR 

Overview

Boris Duchemann practices practicing medicine in Bobigny, France.

Mr. Duchemann is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Acute Interstitial Pneumonia, and Interstitial Lung Disease.

He is actively involved in clinical research, co-authoring 93 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Bobigny, France
Other Locations
Saint-denis-de-palin, France
Villejuif, 94800, France
Paris, France
Aubervilliers, France
Saint-aubin-les-forges, France
Villetaneuse, 93000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Standard Maintenance, Pemetrexed, Durvalumab, Savolitinib, Olaparib
Study Phase: Phase 2
REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer
REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Cis/carboplatin, Etoposide
Study Phase: Phase 2
View 3 Less Clinical Trials

93 Total Publications

Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.
Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2026

Frequently Asked Questions about Boris Duchemann

Is Boris Duchemann a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Boris Duchemann is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Boris Duchemann participate in research or clinical trials?

Yes. Boris Duchemann has published 93 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Boris Duchemann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Duchemann's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile